Blog

Vivek Subbiah: A look at breakthrough treatment for sickle cell anemia

Phota of Vivek Subbiah taken from eurekalert.org

Feb 22, 2024, 23:12

Vivek Subbiah: A look at breakthrough treatment for sickle cell anemia

Vivek Subbiah shared on X:

“Jimi and Victoria met in person for the first time on camera during a Good Morning America segment that aired on February 15 as part of the network’s coverage of Black History Month. Both emotional, they discussed how their lives have improved since they participated in the groundbreaking CRISPR/Cas9 gene-editing trial for Sickle Cell Anemia at Sarah Cannon Docs.

The patient-derived cellular gene therapy used to treat Jimi and Victoria had never been studied before in the community setting & required the experience of a center that works with transplant and cellular therapies.

With its state-of-the-art facilities and partnership with a team of experienced research leaders and physicians in Nashville, SCRI was equipped and prepared to provide access to care for patients through the use of this innovative treatment.

A look at breakthrough treatment for sickle cell anemia Sarah Cannon Docs increasing access to cutting-edge clinical trials & treatment options so all patients have the opportunity to experience improved outcomes.”

View additional information.
Source: Vivek Subbiah/X

Vivek Subbiah is the Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute (USA). He is the former Executive Director of Oncology Research at the MD Anderson Cancer Network and a former Associate Professor in the Department of Investigational Cancer Therapeutics at The University of Texas MD Anderson Cancer Center.

Dr. Vivek Subbiah has served as the principal investigator in over 100 phase I/II trials and co-investigator in over 200 clinical trials and is known for his leadership in several first-in-human and practice-changing studies that directly led to approvals from the FDA, European Medicines Agency, and other agencies across the world. He is an expert in tumor agnostic precision oncology and leads the BRAF and RET tissue agnostic studies to FDA approval.